On July 29, UnitedHealth rose 3.04% in regular trading, trading at $430.22/share, with turnover of $1.271 billion. The stock continued its upward momentum following a blowout Q2 earnings report and a wave of analyst target price upgrades.

UnitedHealth reported Q2 adjusted EPS of $6.38, significantly beating the analyst consensus range of $4.86–$4.91, representing a 56% year-over-year increase. Revenue came in at $112.03 billion versus estimates of $110.81 billion. The company raised its full-year adjusted EPS guidance to $19.50–$20.00, well above the prior Street estimate of $18.49, and announced plans for at least $5 billion in share buybacks. Management noted Medicare medical cost growth is trending below the initial ~10% estimate, supporting further margin improvement.

Following the results, multiple investment banks raised their price targets: Morgan Stanley to $529, Bank of America to $512, Piper Sandler to $499, Cantor Fitzgerald to $495, Mizuho to $493, Jefferies to $490, and RBC to $478, reflecting broad confidence in the earnings recovery trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)